Segment Information (Tables)

12 Months Ended

Dec. 31, 2024

Segment Information

Schedule of significant expense categories reviewed by CODM

	For the year ended December 31,
		2024		2023
Operating expenses:
MB-106 program costs	$	516	$	4,727
MB-109 program costs		487		1,140
All other program costs		(641)		548
Research and development - stock-based compensation		(650)		132
Research and development - other costs (1)		7,845		33,966
Research and development - licenses acquired		861		527
General and administrative - stock-based compensation		201		435
General and administrative - other costs (2)		3,934		9,251
Segment operating loss	$	12,553	$	50,726
Reconciliation to net loss
Asset impairment		(3,692)		-
Gain on sale of property and equipment		-		1,466
Other income (expense), net		314		917
Interest income (expense), net		179		(3,259)
Net Loss	$	(15,752)	$	(51,602)

(1) Includes expenses primarily related to the repurchase of equipment from uBriGene and termination of existing manufacturing and service agreements with uBriGene, lab supplies and software licenses and subscriptions.

(2) Includes expenses primarily related to outside service costs, business insurance and board of director fees.